ANCA-associated vasculitis.
The vasculitides are a heterogeneous group of conditions typified by their ability to cause vessel inflammation with or without necrosis. They present with a wide variety of signs and symptoms and, if left untreated, carry a significant burden of mortality and morbidity. The antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) are three separate conditions - granulomatosis with polyangiitis (GPA; formerly known as Wegener's granulomatosis), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA; previously known as Churg-Strauss syndrome). This review examines recent developments in the pathogenesis and treatment of AAV, focusing on developments in treatment following the introduction of rituximab, in particular.
Norfolk and Norwich University Hospital NHS Foundation Trust, and Norwich Medical School, University of East Anglia, Norwich, UK.
Max
M
Yates
Ipswich Hospital and honorary senior lecturer Norwich Medical School, University of East Anglia, Norwich, UK.
Richard
R
Watts
D056648:Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy; D018501:Antirheumatic Agents; D006801:Humans; D000069283:Rituximab
D018501:Antirheumatic Agents; D000069283:Rituximab
ANCA; diagnosis; rituximab; treatment; vasculitis